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Single nucleotide polymorphism (SNP)a b s t r a c t
Background: The Metabolic syndrome (MetS) is associated with an increased risk of cardiovascular dis-
ease and type 2 diabetes. PON1 and CETP genes may be involved in the pathogenesis of lipid metabolism
and thus MetS. Several single nucleotide polymorphisms of genes were demonstrated to affect their
function. Curcumin (diferuloylmethane) is a yellow pigment of turmeric that has shown numerous phar-
macological activity against obesity and related conditions through anti-oxidant/anti-inflammatory
properties.
Objective: We aimed to assess the association of these polymorphisms with metabolic syndrome and to
investigate if these genetic variants were associated with an altered activity of PON1 and the protein
levels of CETP at base line and after Curcumin supplementation.
Methods: The genotypes of PON1 and CETP polymorphisms were determined in 81 patients with MetS
and 100 healthy individuals using ARMS-PCR and PCR-RFLP techniques.
Results: Individuals with different genotypes of the PON1 rs662, rs854560 and rs705379 polymorphisms
did not differ with paraoxonase activity and CETP serum protein concentrations, either at baseline, or
after intervention. Individuals with different PON1 rs854560 genotypes differ significantly in serum ary-
lesterase activities (p = .037). There were statistically significant differences in genotype frequencies
between cases and controls for CETP rs5882 genotypes (p-value = .034) but not in genotype frequencies
and haplotypes for PON1 studied polymorphisms (p-value < .05). The odds ratio for CETP rs5882 was
statistically significant using a dominant model. OR (95% CI) = 0.48 (025–0.92), p-value = .029.
Conclusions: There were no associations between the PON1 polymorphisms, or haplotypes with MetS.
There was an association between CETPrs5882 and metabolic syndrome. AA genotype of CETPrs5882
appeared to be protective against MetS in our studied population. There were no association between
the PON1 and CETP polymorphisms with PON1enzymatic activities and CETP protein levels at base line
and after curcumin supplementation.
 2018 Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Metabolic syndrome (MetS) is defined by a clustering of cardio-
vascular risk factors including: central obesity, insulin resistance,
hypertension and atherogenic dyslipidemia, and is associated with
a greater risk of type 2 diabetes and cardiovascular disease (CVD)
[1,2].
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one of the highest occurrences worldwide. In the adult population,
a prevalence of 30% in Tehran and 45% in Khorasan province has
been reported [3].
MetS is a multifactorial disorder in which environmental factors
as well as genetic factors play a role [4]. The heritability of MetS
has been estimated to be 24–30% [5,6].
Two genes, PON1 and CETP take part in pathways that may be
involved in the pathogenesis of MetS [7,8].
Paraoxonase 1 (PON1) is involved in the antioxidant defence
system and while it has major catalytic paraoxonase/arylesterase
activities, its physiological substrates are lactones, oxidized-LDL
and homocysteine thiolactone, and hence it may protect against
cardiovascular diseases (CVD) [7].
The paraoxonase gene cluster comprises three members PON1-
PON2-PON3 that are located on chromosome 7q21.3 [9]. More than
160 polymorphisms (SNPs) have been reported for the PON1 gene
[10], of which the Q192R, L55M, -108C/T have been shown to be
associated with serum enzyme protein concentrations and activity.
The Q192R and L55M SNPs are in coding regions and cause an
amino acid substitution. 108C/T is in the promoter of the gene
and affects its expression [7,11,12].
Studies have demonstrated that the serum activity and concen-
trations of PON1 are reduced in conditions in which oxidative
stress may be a contributory factor, such as CVD, Alzheimer, MetS,
aging and higher levels of PON1 may be protective against these
diseases [13].
Cholesterol ester transfer protein (CETP) is a plasma glycopro-
tein expressed in the liver and secreted into the plasma. The CETP
gene is located on the chromosome 16q13, has 16 exons and is 26
kb long[14].
CETP is involved in the exchange of TG on LDL with cholesteryl
esters on HDL, and results in HDL particles that can be degraded by
hepatic lipase. CETP is also involved in reverse cholesterol trans-
port (RCT) and therefore it is not completely clear whether increas-
ing CETP activity would be pro- or anti-atherogenic [8,15–17].
Several SNPs of the CETP gene have been identified which the
I405V causes an isoleusine for valine substitution. In genome wide
association studies (GWAS) it has been found that variation at the
CETP gene locus is associated with low levels of HDL-c and is
related to CVD [18].
Curcumin is a polyphenolic compound derived from turmeric
that has anti-inflammatory and antioxidant properties. It has poor
bioavailability when given orally, but this can be improved by
using a phytosomal complex [19,20]. Phytosomes are chemical
complexes which are synthesized by one or two moles of synthetic
or natural phospholipids mainly phosphatidylcoline, and one mole
of botanical extracts [21].
The aim of this study was to investigate the association
between PON1 and CETP genetic polymorphisms and the presence
of MetS. In addition, the associations of PON1 and CETP genetic
polymorphisms with PON1 enzymatic activities and the serum
concentrations of CETP protein in response to curcumin supple-
mentation was studied in the context of a clinical trial in MetS
patients.
2. Subjects and methods
Blood samples of individuals with MetS were obtained from
subjects who were randomised for a clinical trial study with regis-
tration number of IRCT2014052014521N3 that examined the effi-
cacy of phytosomal curcumin in MetS patients. Volunteers
referred to the Nutrition Clinic of Qaem hospital in Mashhad city
between September to November 2015. A diagnosis of MetS was
made using IDF criteria [1]. All participants gave their written
informed consent to participate in this study, which received theapproval of the Research Council of the Mashhad University of
Medical Science. Patients with kidney disease, systemic lupus
erythematosous (SLE), pregnant women and patients taking anti
hyperlipidemic, or anti hyperglycaemic drugs during the previous
6 months were excluded from the study. The subjects were
randomly allocated to three subgroups receiving either: 1-
phytosomal Curcumin, 2-curcumin and 3-placebo. Then for this
study, groups 1 and 3 were selected as cases (n = 81 of 120 sub-
jects) of the randomised clinical trial study. The work has been car-
ried out in accordance of the Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments in humans
with IR.MUMS.REC.1394.209 reference number. In addition, 100
healthy individuals, sex and age matched with cases were selected
as the control group to conduct this case control study. MetS
patients were treated either with phytosomal curcumin (1mg per
day; group1)/plain curcumin (1g per day-group2) or placebo
(group3) for six weeks. Twenty ml of blood was taken before and
after the intervention period. Anthropometric, demographic and
biochemical parameters were recorded for each subject before
and after the intervention period. The paraoxonase/arylestrase
activity of paraoxonase 1 enzyme and levels of CETP protein before
and after intervention were assessed in all MetS patients. The rela-
tionship between the PON1 rs662, rs854560 and rs705379 geno-
types and serum enzymes paraoxonase/arylestrase activity, and
the CETP5882 genotypes with serum protein concentrations were
determined before and after intervention.
2.1. DNA extraction
DNA was extracted using a DNA extraction kit (Pars tous, Iran)
according to the manufacturer’s instruction and the integrity of
extracted DNA were examined by electrophoresis technique.
2.2. Genotyping
ARMS-PCR and PCR-RFLP were used to identify the various SNP
genotypes, and sequencing was performed to confirm the validity
of these techniques.
2.2.1. ARMS-PCR
ARMS-PCR with 2 different sets of primers was designed to
determine genotypes of PON1 rs662 and CETP rs5882 in patients
and controls. Three primers were used to determine the alleles of
polymorphism and a pair of primers to amplify an internal control
band. Primers to amplify PON1 rs662 were 50-ACTATTTTCTT
GACCCCTACTTATG-30 and 50-CTATTTTCTTGACCCCTACTTTCA-30
and 50-AGTTCACATACTTGCCATCGG-30 with an annealing tempera-
ture of 620c for 35 cycles yielding a 158 bp fragment for allele A and
159 bp for allele G. Primers to amplify CETPrs5882 were 50-
GCAGAGCAGCTCCGAGTACG -30, 50-GCAGAGCAGCTCCGAGTACA -30
and 50-CCGCGGGGTGGCAAAGATAA-30 with an annealing tempera-
ture of 630c for 35 cycles yielding a 311 bp fragment for both alleles
A and G. We also designed a pair of primers to replicate a 408 bp of
HBB gene as an internal control band to check the accuracy of PCR
reactions. The primers were 50-GAAGTCTGCCGTTACTGCCC-30 and
50-GATCCACGTGCAGCTTGTCA-30. The PCR reaction was carried
out for PON1 rs662 in a total volume of 15 ml using Taq DNA
Polymerase 2x Master Mix Red (Ampliqon) and 0.5 pmol/ll of
allele specific primers and 0.3 pmol/ll of internal control primers
and for CETPrs5882 the total volume was 15 ml and the same PCR
conditions as PON1 rs662 but with a greater concentration of
template DNA.
2.2.2. PCR-RFLP
The PON1 rs854560 and rs705379 SNPs each was genotyped
separately by PCR amplification and restriction digest. Primers
Table 2
The relationship of PON1 and CETP polymorphisms with Paraoxonase activity and
CETP protein levels.
PON1 Genotypes Mean ± SD P-value
rs662 AA 0.508 ± 0.176 .775
AG 0.538 ± 0.167
GG 0.535 ± 0.184
Total 75 0.527 ± 0.171
rs854560 AA 0.513 ± 0.16 .767
AT 0.531 ± 0.16
TT 0.566 ± 0.22
Total 76 0.528 ± 0.17
rs705379 CC 0.503 ± 0.17 .385
CT 0.515 ± 0.15
TT 0.577 ± 0.19
Total 75 0.527 ± 0.17
CETPrs5882 AA 0.4338 ± 0.12 .842
AG 0.4622 ± 0.15
GG 0.4365 ± 0.15
Total 43 0.4525 ± 0.14
The results of paraoxones1 activity before intervention are shown that they were
not statistically significant. The results of CETP protein concentrations before
intervention are demonstrate that they are not statistically significant.Comparisons
are performed using one-way ANOVA test. Statistical significance level P-value < .05.
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GAAAGCCTAAGTGA-30 and 50-GGAAAAAGCTCTAGTCCATCAA-30 an
annealing temperature of 61 C for 1 min for 35 cycles. The 403
bp fragment was digested with Hin1II yielded 129 + 274 bp bands
in presence of a T allele. Nevertheless, primers used for rs705379
were 50-TGCAGCCGCAGCCCTGCTGGGGCAGCGCCGATTGGCCCG
CCGC-30 and 50-GACCGCAAGCCACGCCCTCTGTGCACC-30 with an
annealing temperature of 710c for 1 min and 35 cycles [22]. The
digested bands with BstUI were 42 and 67 bp in presence of C
allele. The PCR product size was 109 bp. We also used a sequencing
technique and read the sequence of 14 samples of all 4 SNPs to
confirm the results of our genotyping. All results were the same
as previously determined.
2.3. Statistical analysis
The data were analysed by using SPSS version 16. Statistical sig-
nificance was considered at a P < .05. Discrete data were analysed
by Chi-square test. Continuous data was assessed for normality
using the Kolmogorov-Smirnov test. Independent sample T-Test
and One – Way ANOVA tests were used to evaluate normally
distributed variables and were expressed as means with their
standard deviation. Mann-Whitney and Kruskal-Wallis tests were
used for non-normally distributed variables and are expressed as
medians and interquartile ranges. Hardy-Weinberg analysis were
performed to assess the genotype distributions. Case-control geno-
typic and allelic distribution were calculated using v2 statistics.
The Odds ratio (OR) with 95% confidence intervals (95% CI) was
estimated in dominant, recessive and multiplicative models for
all SNPs after determining risky alleles. The Bonferonni correction
was made for multiple testing. Haplotype analysis was conducted
by PHASE software (http://stephenslab.uchicago.edu/software.
html#phase).
3. Results
Anthropometric, demographic and biochemical parameters of
the studied population are shown in Table 1. There was no differ-
ence in age between cases and controls as they were matched for
this. Other parameters as expected were higher in patients, except
for serum HDL-c that was lower in patients (Tables 2–5)
Statistical significance level P-value < .05. Normally distributed
variables expressed as mean ± SD. Non-normally distributed vari-
ables are expressed as median and interquartile range.
HDL-C: high-density lipoprotein cholesterol, WC: waist circum-
ference, SBP systolic blood pressure, DBP diastolic blood pressure,
TG: triglycerides, FBG: fasting blood glucose.
3.1. Relationship of PON1 polymorphisms with Paraoxonase/
Arylesterase activity and CETP polymorphism with protein level
The relationship of PON1 rs662, rs854560 and rs705379 geno-
types with enzyme paraoxonase activity and CETP5882 genotypesTable 1
Anthropometric, demographic and biochemical parameters of the study subjects.
Variable Case Control P-value
BMI (kg/m2) 26.47 ± 4.42 30.82 ± 4.79 <.05
Cholesteryl(mg/dl) 175.37 ± 3.04 240.79 ± 5.31 <.05
HDL-C (mg/dl) 48.71 ± 10.7 52.09 ± 11.92 <.05
Age(year) 42(16.25) 38(4.75) 0.781
Weight(kg) 79.60(16.90) 67(14.75) <.05
WC(cm) 101(11) 88(13.75) <.05
SBP(mmHg) 122(18) 110.67(14.92) <.05
DBP(mmHg) 79(9) 75(10) <.05
TG(mg/dl) 149.5(101.5) 87.5(46) <.05
FBS(mg/dl) 95(26) 80(16.75) <.05with protein level before and after intervention were not signifi-
cant. The differences of arylesterase activities between genotypes
of PON1 rs662 and rs705379 genotypes was not statistically signif-
icant. Nevertheless, rs854560 genotypes showed statistically sig-
nificant differences in arylesterase activities before intervention
(p = .037).
3.2. Association of PON1 polymorphisms with metabolic syndrome
PON1rs662, rs854560 and rs705379 genotypes were in Hardy-
Weinberg equilibrium in cases and controls and in total studied
population (p-value > 0.05). CETP rs5882 genotypes in controls
and studied population were in Hardy-Weinberg equilibrium (p-
value > .05) but in cases genotypes were not in Hardy-Weinberg
equilibrium (p-value = .035).
The difference of allele and genotype frequencies of PON1rs662,
rs854560 and rs705379 polymorphisms between cases and con-
trols was not statistically significant (p-value > .05). The Odds ratio
estimated for the risky alleles for PON1rs662, rs854560 and
rs705379 were not statistically significant (p-value > .05). There
was however a statistically significant difference in genotypes
frequencies between cases and controls in CETP rs5882 (p-value =
.034). The estimated odds ratio was statistically significant in the
dominant model OR (95%CI) = 0.48 (0.25–0.92).
3.3. Haplotype analysis in the studied population
Haplotype frequencies of PON1 desired polymorphisms in cases,
controls and the whole population were estimated by PHASE
software.
The p-value was estimated as 0.08 and showed that there was
no statistically significant difference in haplotype distribution
between cases and controls.4. Discussion
Early diagnosis and treatment of the MetS can be one strategy
to prevent cardiovascular disease and type 2 diabetes mellitus.
Table 4
Genotype Frequency distribution of PON1rs662 of the study subjects.
Study Group (No.) Genotypes p-value Alleles p-value OR(95%CI) p-value
N(%) N(%) N(%) N(%) N(%)
PON1rs662 AA AG GG 0.15 A G 0.09 1.46(0.94–2.30) 0.09
Case (79) 27(34.2) 42(53.2) 10(12.7) 96(60.75) 62(39.24)
Control (100) 44(48.9) 37(41.1) 9(10) 125(69.44) 55(30.55)
PON1rs854560 AA AT TT 0.93 A T 1 1(0.65–1.55) 1
Case (80) 31(38.8) 42(52.5) 7(8.8) 104(65) 56(35)
Control (100) 40(40) 50(50) 10 (10) 130(65) 70(35)
PON1rs705379 CC CT TT 0.28 C T 0.13 1.38(0.90–2.11) 0.13
Case (77) 17(22.1) 43(55.8) 17(22.1) 77(50) 77(50)
Control (100) 32(32) 52(52) 16(16) 116(58) 84(42)
CETPrs5882 AA AG GG 0.34 A G 0.24 1.29(0.84–1.97) 0.24
Case (79) 20(25.3) 50(63.3) 9(11.4) 90(56.96) 68(43.03)
Control (100) 41(41) 44(44) 15(15) 126(63) 74(37)
*Dominant model AA AG + GG 0.48(0.25–0.92) 0.029 [0.1]+
Comparisons are performed using the v2 test. Statistical significance level P-value < .05. +p-value after Bonferroni correction (multiple testing). *The odds ratio was of
Statistical significance for CETPrs5882 in the dominant model. All other models were analysed for odds ratio however there was no significant difference (data has only been
shown for the Multiplicative model for PON1rs662, rs854560, and rs705379).
Table 3
The relationship of PON1polymorphisms with arylesterase activity.
SNP Variable Median Percentile P-value
25th 75th
rs662 arylesterase 145.54 89.05 206.106 0.331
rs854560 arylesterase 149.109 89.05 206.106 0.037*
rs854560 Average Activity 156.87 89.05 206.106 0.035*
rs705379 arylesterase 141.47 89.05 206.106 0.425
The results of arylesterase activity of rs662 and rs705379 genotypes before intervention was shown that these were not statistically significant. *The results of arylesterase
activity of rs854560 genotypes was shown that before intervention and the average activities were significant. Comparisons are performed using Kruskal-Wallis test.
Statistical significance level P-value < .05.
Table 5
Haplotype frequencies in Case, Control and studied population.
Haplotype Total Case Control
111 (CAA) 0.303 0.298 0.307
112(CAG) 0.141 0.139 0.143
121 (CTA( 0.087 0.051 0.116
112 (CTG) 0.013 0.013 0.012
211 (TAA) 0.068 0.054 0.079
212 (TAG) 0.136 0.157 0.119
221 (TTA) 0.194 0.203 0.188
222 (TTG) 0.055 0.082 0.033
P-value for testing H0: Cases  Controls = 0.08, Statistical significance level
P-value < .05.
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prehensive understanding of the underlying pathophysiology lead-
ing to the disease is required and genetic studies may be useful.
Our findings revealed that there was no association between
PON1rs662, rs854560 and rs705379 and MetS.
One similar study has been conducted in the south-east of Iran
in which it was reported that there was an association between the
PON1 polymorphisms and the risk of MetS. For PON1rs662, carriers
of AG + GG and GG genotypes had an increased risk of MetS.
However, the calculated risk for rs854560 and rs705379 was not
statistically significant [23].
The different results of the two studies may be due to different
sample sizes, allele frequencies and life styles (different Iranian
minorities) which may therefore influence the risk of MetS. More-
over because of the lack of Hardy-Weinberg analysis, the interpre-
tation of these results may be difficult. Allele frequencies of PON1polymorphisms have shown widely different distributions among
populations. In the South-east of Iran, the minor allelic frequency
of PON1rs662 is 32%, rs854560 is 50% and rs705379 is 32% in
healthy individuals [23] while in our study, they were 30.55%,
35% and 42% respectively. only allele frequencies of the PON1rs662
was similar in these two populations. In our study population, the
frequency of rs662 allele A was 69.44% and G 30.55% similar to the
South-east of Iran that had allele A 68% and G 32% frequent.
Whereas, rs854560 both alleles, A and T were 50% frequent and
rs705379 allele C 68% and T 32% frequent in the South-east of Iran.
In our population, they were: A 65% and T 35% for rs854560 and C
58% and T 42% for rs705379.
The allele distribution of rs662 and rs854560 in our population
is similar to that reported in a study based in Spain (rs662 = 0.30%,
rs854560 = 0.37%, rs705379 = 0.54%) [24] and to an Italian study
where rs662, rs854560 and rs705379 allele frequencies have been
reported as 0.35%, 0.34%, 0.43% respectively) [11]. In our study the
minor allele frequencies of the PON1rs854560 T allele was esti-
mated as 35% in both cases and controls.
Other oxidative stress related conditions like cardiovascular
diseases, Alzheimer’s and cancer have also shown various preva-
lence and results of association with PON1 polymorphisms in
different ethnicities based on various studies [7]. Also, it is demon-
strated that genetic confounding or population stratification effects
explain contradiction of association studies [25].
We have also found that there was no significant difference
among genotypes of each PON1polymorphisms in serum paraox-
onase activity. Possible reasons for this result may be due to a
small sample size, as when considering the means of enzyme
paraoxonase activities there is a difference but it was not
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terase activity and PON1rs854560 but not with rs662 and
rs705379. The mean arylesterase activities of AG genotypes of
rs85450 was higher than other genotypes which may be due to
the number of heterozygotes that was higher in this studied pop-
ulation or that this genotype is in linkage disequilibrium with
allele C of rs705379 that shows a higher concentration and enzyme
arylesterase activity.
In the present study, we found that there was no association
between haplotypes of the PON1polymorphisms and the presence
of MetS in this population.
Most of the association studies of haplotypes of PON1 polymor-
phisms are focused on obesity, and their relationship with meta-
bolic syndrome have not been assessed independently [26–28].
We found a weak association between CETPrs5882 polymor-
phism and MetS. In our population two copies of allele A had a
protective effect. However, after Bonferroni correction this was
not significant.
Studies similar to our research have not been carried out. Few
studies have demonstrated positive association of CETP level and
obesity [29–31].
In various studies, the frequency of I405V alleles has been
reported differently due to differences in sample size, ethnic
groups and geographical places. However in every source, allele
G has been known as a minor allele with 25% frequency [32]. The
frequency of allele G was 0.37% in our population. It was 0.35%
in Azerbaijan, almost similar to the Caucasian population with%
32 [33] in Ahvaz (the south-west of Iran) it was 0.37 [34] and
Tehran 0.36% [35]. It was 0.617 in Asia and 0.611 in the African-
American population [36].
In this study, there was no significant difference in CETP levels
between genotypes. The protein level was measured in patients
but was not done in controls.
Some studies have considered VV genotype as a risk factor for
CHD [36] while others mentioned it as a protective effect against
CAD [37].
It was thought that because CETP increases LDL level and
decreases HDL-c, it may have a destructive effect on the heart
and arteries despite the fact that the use of CETP inhibitor drugs
increased stroke in patients in phase 3 clinical trials [37]. Therefore
this protein cannot have a simple and direct relationship with lipid
profile and risk of the diseases, and so more studies are essential.
This result is consistent with previous studies reporting no
association between certain genetic variants (e.g. TNF-a G-308A
polymorphism) and the presence of Met.S [38].
The full explanation of the results of the randomised clinical
trial study is not in the scope of our study. However, the non-
significant results of the effect of genotypes on PON1 enzymatic
activities and CETP concentrations is possibly due to insufficient
sample size, the influence of life style, ethnicity or biochemical
factors (HDL-c, TG, cholesterol) on enzymes.
5. Conclusions
In conclusion, we could not find any association between PON1
rs662, rs854560 and rs705379 genotypes and haplotypes with the
risk of metabolic syndrome. However we found an association
between CETP rs5882 genotypes and the presence of metabolic syn-
drome. Also having two A allele for CETP rs5882 may confer some
degrees of protection. Moreover, it seems that neither CETP con-
centration nor PON1 activity may be affected by the genotype in
this study.
Curcumin supplementation had no considerable effects on
PON1 Paraoxonase/Arylesterase activity and CETP protein levels
among three groups of MetS patients (1-phytosomal Curcumin,
2-plain curcumin and 3-placebo) before and after intervention.Acknowledgment
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